How does Zimmer Biomet make money?

ZIMMER BIOMET HOLDINGS, INC. – Business Breakdown

The Essentials

Zimmer Biomet Holdings, Inc. is a global orthopedic medical device manufacturer with a concentrated but diversified portfolio spanning reconstructive orthopedic implants, sports medicine products, biologics, trauma solutions, and surgical technologies. The company operates across three geographic segments — Americas, EMEA, and Asia Pacific — and derives the majority of its revenue from the U.S. market, which accounted for 57.6% of total sales in the nine months ended September 30, 2025.

At its core, the business is anchored in large, mature orthopedic categories, particularly knees and hips, which together represented 65.0% of revenue over the period. That concentration underscores both the company’s scale in joint reconstruction and its exposure to a highly competitive, increasingly commoditized market. At the same time, Zimmer Biomet is actively broadening its footprint into adjacent areas such as S.E.T. (sports, extremities, trauma), which contributed 18.3% of revenue, and into digital and robotic surgical technologies through its ZBEdge® Platform.

From an investor perspective, the profile is that of a company with meaningful installed-base economics, recurring revision demand, and broad procedural relevance — but also one facing margin pressure, integration complexity, and a competitive environment that limits pricing power.

Business Model & Revenue Drivers

Zimmer Biomet generates economic value through the design, manufacture, and commercialization of orthopedic and surgical products sold through direct sales forces, independent agents, distributors, and institutional channels such as GPOs and managed care accounts. Its revenue mix reveals the company’s principal value drivers:

• Knees – 40.3% of revenue

  • The largest product category and the clearest anchor of the franchise.
  • Includes primary, revision, and unicompartmental procedures.
  • Key brands cited include Persona® Knee, NexGen® Knee Implants, Vanguard® Knee, and Oxford® Partial Knee.
  • This category is strategically important because it combines high procedural relevance with installed-base support for future revision demand.

• Hips – 24.7% of revenue

  • The second major reconstructive pillar.
  • Benefits from a significant installed base, which supports recurring revision procedures.
  • Like knees, hips are central to the company’s exposure to mature but high-volume orthopedic demand.

• S.E.T. (Sports, Extremities, Trauma) – 18.3% of revenue

  • A diversification vector beyond core joint reconstruction.
  • Includes sports medicine, biologics, foot/ankle, upper extremities, trauma, and CMFT products.
  • Sports medicine represented 13% of the S.E.T. category, while biologics represented 6%, indicating a mix of soft tissue repair and joint-preservation solutions.

• Other revenue – 16.7% of revenue

  • Includes technology and data, bone cement, and surgical solutions.
  • The ZBEdge® Platform sits within this broader technology layer and is strategically relevant as a differentiator in an otherwise price-pressured market.

Geographically, the company’s revenue base is split between:

• United States: 57.6%
• International: 42.4%

This mix provides scale and diversification, but also exposes the company to foreign exchange volatility and region-specific reimbursement pressure, particularly in Europe. The business is therefore driven not only by procedure volumes, but also by pricing discipline, product mix, and the ability to defend share in mature markets while expanding in adjacent categories.

Strategic Edge & Market Positioning

Zimmer Biomet’s competitive position appears to rest more on execution quality than on an impregnable structural moat. The source material describes a moderate, eroding structural moat, with the most meaningful advantages arising from surgeon familiarity, installed base effects, and distribution scale.

Economic Moat

• Switching costs: Moderate to high in practice, because surgeons develop familiarity with specific implant systems and hospitals tailor inventory and protocols around them.
• Installed base: Meaningful, especially in knees and hips, where revision procedures can create recurring demand.
• Brand recognition: Established product names such as Persona®, NexGen®, and Oxford® support surgeon preference and clinical familiarity.
• Scale and distribution: The company has a global manufacturing and sales footprint, which supports market access.

That said, the source is explicit that these advantages are not fully durable:

• There are no network effects.
• There is no clear cost leadership.
• Patent protection is limited by challenge and design-around risk.
• Knee and hip implants are increasingly commoditized, intensifying price competition.
• Competitors such as Stryker, Johnson & Johnson/DePuy Synthes, and Smith & Nephew possess comparable or superior scale.

Execution Advantage Zimmer Biomet’s current positioning is therefore better understood as an execution-driven franchise:

• It has a broad commercial footprint.
• It maintains surgeon relationships and procedural familiarity.
• It is actively managing product breadth through acquisitions and technology investment.
• It is attempting to offset commoditization through robotics, digital workflow, and adjacent-market expansion.

For sophisticated investors, the key distinction is that this is not a business with a deeply entrenched structural moat. Rather, it is a strong operating platform whose competitive standing depends on sustained execution, product refresh, and disciplined capital deployment.

Outlook & Innovation Pipeline

The next three years appear to be centered on three strategic priorities: defending the core, expanding adjacencies, and upgrading the technology stack.

• ZBEdge® Platform commercialization and adoption

  • The platform combines robotic and digital technologies for surgical guidance and data collection before, during, and after surgery.
  • Its strategic role is to create differentiation in a commoditized orthopedic market and potentially support pricing power.

• Robotic surgery development

  • The company is developing a surgical robot for patient-optimized orthopedic implant placement in the U.S.
  • This is strategically important given competitive pressure from robotic platforms offered by peers.
  • The filing does not provide a clear commercialization timeline, so the near-term impact remains uncertain.

• Adjacency expansion through acquisitions

  • Embody, Inc. expands exposure to craniomaxillofacial products.
  • Paragon 28, Inc. strengthens the foot/ankle position.
  • These moves indicate a deliberate effort to reduce dependence on knees and hips and to access higher-growth orthopedic niches.

• Biologics, sports medicine, and trauma

  • These categories remain important growth vectors within S.E.T.
  • They broaden the company’s relevance beyond reconstructive implants and support a more diversified orthopedic platform.

• Operational efficiency and restructuring

  • The company is executing a 2025 Restructuring Plan and has completed the 2023 Restructuring Plan, which generated $117 million in pre-tax charges.
  • This suggests management is actively addressing margin pressure and cost structure inefficiencies.

Overall, the innovation pipeline is strategically coherent: Zimmer Biomet is trying to defend its legacy implant franchise while building a more technology-enabled and diversified orthopedic platform. The investment case over the next three years will likely hinge on whether these initiatives can translate into improved margin performance, better mix, and more durable competitive positioning.